Daniela Dornelles Rosa

List of Publications by Year
in descending order

34 papers	952 citations	471509	454955
		17 h-index	30 g-index

35 all docs	35 docs citations	35 times ranked	1947 citing authors

#	Article	IF	Citations
1	Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. European Journal of Pharmaceutical Sciences, 2010, 41, 458-463.	4.0	117
2	Novel cytotoxic drugs: Old challenges, new solutions. Cancer Treatment Reviews, 2008, 34, 81-91.	7.7	83
3	Incidence of Cancer Following Bariatric Surgery: Systematic Review and Meta-analysis. Obesity Surgery, 2014, 24, 1499-1509.	2.1	79
4	The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treatment Reviews, 2007, 33, 64-77.	7.7	69
5	Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis. Breast Cancer Research and Treatment, 2011, 126, 273-285.	2.5	69
6	Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast, 2019, 44, 113-119.	2.2	68
7	Chronic mucocutaneous candidiasis and oesophageal cancer. Medical Mycology, 2008, 46, 85-91.	0.7	50
8	Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews, 2008, 34, 61-80.	7.7	45
9	Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. Breast Cancer Research and Treatment, 2018, 170, 455-476.	2.5	40
10	Sensitive HPLC–PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2013, 76, 13-20.	2.8	37
11	Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype. Therapeutic Drug Monitoring, 2012, 34, 422-431.	2.0	31
12	The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). Breast Cancer Research and Treatment, 2020, 183, 749-757.	2.5	31
13	*CYP3A4*22* is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. Pharmacogenomics, 2015, 16, 601-617.	1.3	24
14	Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation. Therapeutic Drug Monitoring, 2015, 37, 733-744.	2.0	21
15	Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Science, 2007, 98, 844-849.	3.9	19
16	Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). JCO Global Oncology, 2021, 7, 649-658.	1.8	19
17	The Best Guess Approach to Phase I Trial Design. Journal of Clinical Oncology, 2006, 24, 206-208.	1.6	16
18	Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Archives of Gynecology and Obstetrics, 2008, 278, 457-462.	1.7	14

#	Article	IF	Citations
19	Antiangiogenic therapy for ovarian cancer. Current Opinion in Oncology, 2007, 19, 497-505.	2.4	12
20	Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Current Opinion in Molecular Therapeutics, 2005, 7, 493-501.	2.8	10
21	Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions. Drug Safety, 2022, 45, 601-621.	3.2	10
22	Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates. Breast Care, 2018, 13, 447-452.	1.4	9
23	Breast cancer survival in Brazil: How much health care access impact on cancer outcomes?. Breast, 2020, 54, 155-159.	2.2	9
24	Deficiency of the eighth component of complement associated with recurrent meningococcal meningitis: case report and literature review. Brazilian Journal of Infectious Diseases, 2004, 8, 328-330.	0.6	8
25	Accuracy of telomerase in estimating breast cancer risk: A systematic review and meta-analysis. Breast, 2012, 21, 1-7.	2.2	7
26	Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients. Clinical Biochemistry, 2014, 47, 1084-1090.	1.9	7
27	Trastuzumab (Herceptin) for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 239-256.	2.2	6
28	Retrospective study of 668 cultures for mycobacteria in a reference hospital for AIDS in Southern Brazil. Brazilian Journal of Infectious Diseases, 2003, 7, 126-8.	0.6	5
29	OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy. Journal of Clinical Oncology, 2006, 24, 5176-5177.	1.6	4
30	Biological features of breast cancer according to age at diagnosis in southern Brazil: An analysis of retrospective data of 1128 women. Breast Journal, 2019, 25, 760-762.	1.0	4
31	Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review. Current Oncology Reports, 2021, 23, 63.	4.0	3
32	Textbook of Uncommon Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 1259.	7.4	2
33	Brain imaging and treatment modality of central nervous system metastasis: A single‐institution cohort. Breast Journal, 2020, 26, 812-814.	1.0	0
34	What Cancer Patients Want to Know? Questions from Oncologic Patients in a Brazilian Private Cancer Center. Journal of Cancer Education, 2021, 36, 106-109.	1.3	0